Making partnership working business as usual ...

While pharma invests heavily in AI technologies, many healthcare professionals (HCPs) are quietly disengaging from the ...

The industry is facing a structural paradox. Breakthrough therapies are becoming more complex and targeted, but bringing them to market is slower, more expensive and more uncertain. Up to 90% of ...

Under this pressure, manufacturers are being forced to rethink how they operate. Speed is no longer just one performance metric among many – it has become central to the entire business model, ...

Palisade Bio has released further phase 1a/b analyses of its investigational PDE4 inhibitor prodrug PALI‑2108, adding new ...

A new phase 2 clinical trial has opened at Roswell Park Comprehensive Cancer Center to evaluate the cancer vaccine SurVaxM in ...

Boehringer Ingelheim has reported positive topline results from the phase III SYNCHRONIZE‑1 trial, showing that its ...

BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...

David Apelian, CEO of Theolytics, said: “We are proud to announce the dosing of the first patient in this important study.” ...

The UK’s Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia (clesrovimab), ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...